Showing 62 search results
Call the dedicated Gamunex Connexions team today at 1-888-MYGAMUNEX (1-888-694-2686).
Live, personalized support from Gamunex Connexions
Call the dedicated Gamunex Connexions team today at 1-888-MYGAMUNEX (1-888-694-2686).
CIDP is a rare, progressive autoimmune disease that involves nerve damage or dysfunction in the arms and legs.
What GAMUNEX-C is doing inside the body
Treatment with GAMUNEX-C provides antibodies to block the immune and inflammatory processes that are attacking the protective covering of the nerve fibers.
Clinical Resources for the Treatment of PIDD
GAMUNEX-C offers you insights and resources for the treatment of PIDD.
What are the side effects of CIDP?
See the most common and serious side effects of treatment with GAMUNEX-C.
Educational brochures for CIDP and PIDD
Download helpful brochures to learn more about these conditions and available treatments.
Learn about intravenous infusions and what to expect from your treatment with GAMUNEX-C.
What you can expect with GAMUNEX-C
Learn about intravenous infusions and what to expect from your treatment with GAMUNEX-C.
Call Grifols Customer service at 1-800-243-4153 or write us at 79 TW Alexander Dr, STE 4101, Durham, NC 27713-2920.
Gamunex Connexions offers financial help for your patients and administrative help for your office.
Gamunex Connexions Support Program for CIDP Patients
Gamunex Connexions offers financial help for your patients and administrative help for your office.
Learn about GAMUNEX-C for the the treatment of CIDP
GAMUNEX-C for Patients Homepage
Learn about GAMUNEX-C for the the treatment of CIDP
Sign up for Gamunex Connexions to get information and financial support.
Gamunex Connexions Support Program
Sign up for Gamunex Connexions to get information and financial support.
Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.
Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.
Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.
Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.
Contact your GAMUNEX-C representative
If you would like to talk with a medical science liaison, please contact a sales representative to set up a time for you with this form.
A single point of contact for all your needs.
Dedicated support from Gamunex Connexions.
A single point of contact for all your needs.
The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.
Dosing and Administration for GAMUNEX-C
The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.
Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C.
Office Resources and Support for PIDD
Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C.
PI stands for primary immunodeficiency (PI). In PI, part of your immune system is missing or doesn't function properly.
GAMUNEX-C may meet the needs of a variety of CIDP patients.
GAMUNEX-C contains no sugar or preservatives and only trace amounts of sodium.
Connecting you to educational resources about treatment
Understanding your CIDP symptoms
Symptoms of CIDP can resemble other diseases, such as MS, ALS or GBS. That's why it's important to tell you doctor about all your symptoms.
What is the maximum purity of IgG?
Unique caprylate/chromatography fractionation and purification process with maximum percentage of IgG ≥98%
Use this form to sign up for Gamunex Connexions to receive more information.
If you have general questions about Grifols or GAMUNEX-C, contact us through this form.
GAMUNEX-C is IG therapy for the treatment of CIDP and is the standard of care.
CIDP can be challenging to diagnose. It takes a combination of clinical assessments and diagnostictc tests.
How is CIDP diagnosed and treated?
CIDP can be challenging to diagnose. It takes a combination of clinical assessments and diagnostictc tests.
Common questions about GAMUNEX-C and CIDP.
Learn about how GAMUNEX-C may help improve symptoms.
What to expect when taking GAMUNEX-C
Learn about how GAMUNEX-C may help improve symptoms.
Connecting you with educational resources about treatment
Real people with CIDP share their stories from diagnosis to treatment.
Sign up to receive information about PI, GAMUNEX-C, and support resources.
Gamunex Connexions Support Program
Sign up to receive information about PI, GAMUNEX-C, and support resources.
A proven 10% IG option in the treatment of PIDD.
A proven 10% IG option in the treatment of PIDD.
Use this form to sign up for Gamunex Connexions to receive more information.
The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.
Dosing and Administration for GAMUNEX-C
The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.
Unique caprylate/chromatography fractionation and purification process with maximum percentage of IgG ≥98%
What is maximum purity of IgG?
Unique caprylate/chromatography fractionation and purification process with maximum percentage of IgG ≥98%
Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.
Chronic inflammatory demyelinating polyneuropathy is complex
Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.
Call Grifols Customer Service at 1-800-243-4153 or write us at 79 TW Alexander Drive, STE 4101, Durham, NC 27713-2920.
GAMUNEX-C fights inflammation, has proven tolerability, and reduces the impact of CIDP on patients' lives.
GAMUNEX-C fights inflammation, has proven tolerability, and reduces the impact of CIDP on patients' lives.
Eligible patients can get up to $10,000 in copay assistance. Subject to terms and conditions.
Financial Support from Gamunex Connexions
Eligible patients can get up to $10,000 in copay assistance. Subject to terms and conditions.
Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C
Office Resources and Support for CIDP
Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C
Approved for both IV and subcutaneous administration for your PIDD patients 2 years of age and older
Dosing and Administration methods for PIDD patients
Approved for both IV and subcutaneous administration for your PIDD patients 2 years of age and older
Use this form to sign up for Gamunex Connexions to receive more information.
Connecting you with educational resources about treatment
What are the symptoms of CIDP?
CIDP symptoms can vary from person to person and usually occur on both sides of the body at the same time.
Patient Assistance from Gamunex Connexions.
You may be qualified to receive GAMUNEX-C at no cost. Terms and conditions apply.
~2X fewer PIDD patients with validated infections in a head-to-head trial vs Gamimune® N 10%.
Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.
Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.
Important Safety Information
View CloseGAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) is indicated for the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older, idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IVIG) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
GAMUNEX-C is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Severe hypersensitivity reactions may occur with IVIG products, including GAMUNEX-C. In case of hypersensitivity, discontinue GAMUNEX-C infusion immediately and institute appropriate treatment.
Monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
There have been reports of aseptic meningitis, hemolytic anemia, and noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) in patients administered with IVIG, including GAMUNEX-C.
The high-dose regimen (1g/kg x 1-2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern.
Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Do not administer GAMUNEX-C subcutaneously in patients with ITP because of the risk of hematoma formation.
Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMUNEX-C and at appropriate intervals thereafter.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis.
If signs and/or symptoms of hemolysis are present after an infusion of GAMUNEX-C, perform appropriate laboratory testing for confirmation.
If TRALI is suspected, perform appropriate tests for the presence of antineutrophil antibodies and anti-HLA antibodies in both the product and patient's serum.
After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.
In clinical studies, the most common adverse reactions with GAMUNEX-C were headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, and asthenia (in CIDP); cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis with intravenous use (in PIDD) and local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia with subcutaneous use (in PIDD); and headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, and dyspepsia (in ITP).
The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in 1 subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in 1 subject (in PIDD), and myocarditis in 1 subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Please see accompanying full Prescribing Information for GAMUNEX-C.
GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) is indicated for the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older, idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IVIG) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
GAMUNEX-C is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Severe hypersensitivity reactions may occur with IVIG products, including GAMUNEX-C. In case of hypersensitivity, discontinue GAMUNEX-C infusion immediately and institute appropriate treatment.
Monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
There have been reports of aseptic meningitis, hemolytic anemia, and noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) in patients administered with IVIG, including GAMUNEX-C.
The high-dose regimen (1g/kg x 1-2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern.
Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Do not administer GAMUNEX-C subcutaneously in patients with ITP because of the risk of hematoma formation.
Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMUNEX-C and at appropriate intervals thereafter.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis.
If signs and/or symptoms of hemolysis are present after an infusion of GAMUNEX-C, perform appropriate laboratory testing for confirmation.
If TRALI is suspected, perform appropriate tests for the presence of antineutrophil antibodies and anti-HLA antibodies in both the product and patient's serum.
After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.
In clinical studies, the most common adverse reactions with GAMUNEX-C were headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, and asthenia (in CIDP); cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis with intravenous use (in PIDD) and local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia with subcutaneous use (in PIDD); and headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, and dyspepsia (in ITP).
The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in 1 subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in 1 subject (in PIDD), and myocarditis in 1 subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Please see accompanying full Prescribing Information for GAMUNEX-C.
Important Safety Information
GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) is indicated for the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older, idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IVIG) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIG products containing sucrose. GAMUNEX-C does not contain sucrose. For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable.
GAMUNEX-C is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Severe hypersensitivity reactions may occur with IVIG products, including GAMUNEX-C. In case of hypersensitivity, discontinue GAMUNEX-C infusion immediately and institute appropriate treatment.
Monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IVIG treatment, including GAMUNEX-C.
There have been reports of aseptic meningitis, hemolytic anemia, and noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) in patients administered with IVIG, including GAMUNEX-C.
The high-dose regimen (1g/kg x 1-2 days) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern.
Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Do not administer GAMUNEX-C subcutaneously in patients with ITP because of the risk of hematoma formation.
Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMUNEX-C and at appropriate intervals thereafter.
Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis.
If signs and/or symptoms of hemolysis are present after an infusion of GAMUNEX-C, perform appropriate laboratory testing for confirmation.
If TRALI is suspected, perform appropriate tests for the presence of antineutrophil antibodies and anti-HLA antibodies in both the product and patient's serum.
After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.
In clinical studies, the most common adverse reactions with GAMUNEX-C were headache, pyrexia, hypertension, chills, rash, nausea, arthralgia, and asthenia (in CIDP); cough, rhinitis, pharyngitis, headache, asthma, nausea, fever, diarrhea, and sinusitis with intravenous use (in PIDD) and local infusion-site reactions, fatigue, headache, upper respiratory tract infection, arthralgia, diarrhea, nausea, sinusitis, bronchitis, depression, allergic dermatitis, migraine, myalgia, viral infection, and pyrexia with subcutaneous use (in PIDD); and headache, ecchymosis, vomiting, fever, nausea, rash, abdominal pain, back pain, and dyspepsia (in ITP).
The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in 1 subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in 1 subject (in PIDD), and myocarditis in 1 subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Please see accompanying full Prescribing Information for GAMUNEX-C.